StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
688203.SS$12.00-2.99%
Fair $12.00+0.0%

688203.SS

Zhejiang Hisun Biomaterials Co.Ltd.

Basic Materials / ChemicalsShanghai

$12.00

-0.37 (-2.99%)

Fairly Valued+0.0%Fair Value $12.00Fund rank 27/100 · Data gapFallback financials|
SA 39/D
F-Score: 4/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $-106.3M · quality 61.0/100

Data gap 27/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 21/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

39/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Sector-specific commodity mid-cycle model required: targets are disabled until normalized cycle price/cost-curve/reserve data exists. ROE is 0.7%, below the 5% threshold
Thesis & Journal · 688203.SSLocal privado en este navegador · Zhejiang Hisun Biomaterials Co.Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$2.4B

P/E

240.0x

↑

EV/EBITDA

23.9x

↑

ROE

0.7%

↑

Gross Margin

10.7%

↓

Debt/Equity

0.14

↓
52-Week Range$12
$10$18

TradingView lightweight chart

688203.SS price, volumen y niveles de valoración

Último $12.00Periodo -42.4%
Fair value: $12.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+12.0%

FCF CAGR

—

FCF margin

-12.5%

FCF / Net income

-10.78x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $851.7M · net income $9.9M · FCF $-106.3M

2022-FY → 2025-FY

Gross margin

10.7%-2.6% pts

Operating margin

2.5%-4.3% pts

Net margin

1.2%-6.6% pts

FCF margin

-12.5%+2.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$851.7M$851.7M$845.2M$753.3M$605.4M
Net Income$9.9M$9.9M$35.5M$43.5M$47.0M
EBITDA$93.8M$93.8M$120.3M$115.5M$105.1M
EPS0.050.050.180.210.28
Gross Margin10.7%10.7%12.5%13.1%13.4%
Operating Margin2.5%2.5%5.5%5.4%6.8%
Net Margin1.2%1.2%4.2%5.8%7.8%
Balance Sheet
Debt/Equity0.140.140.130.170.19
Current Ratio1.431.43———
Cash Flow
Free Cash Flow$-106.3M$-106.3M$-254.3M$-51.1M$-89.1M
Returns
ROE0.7%0.7%2.4%2.9%3.2%
Valuation
P/E240.00240.0051.7860.6259.50
EV/EBITDA23.9323.9312.6517.6920.29
P/B1.601.601.231.781.93
Growth & Yield
Revenue Growth0.8%0.8%12.2%24.4%—
EPS Growth-72.2%-72.2%-14.3%-25.0%—
Dividend Yield0.5%0.5%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

177.2%

muy exigente

EPS terminal req.

$1.06

Spread vs growth

-249.4%

5Y implied EPS CAGR

91.5%

muy exigente

EPS terminal req.

$1.29

Spread vs growth

-163.7%

10Y implied EPS CAGR

45.1%

muy exigente

EPS terminal req.

$2.07

Spread vs growth

-117.4%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +15.4%

Total return

+15.4%

Start / end P/E

58.0x → 240.0x

EPS bridge

0.18 → 0.05

Residual

-226.6%

EPS growth-72.2%
Multiple rerating+313.8%
Dividend+0.5%
Residual / FX / buybacks / cross-term-226.6%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.